A 2026 review concluded that GLP-1 receptor agonists have plausible stroke biology and modest prevention signals, but current human evidence does not support routine use as acute ischemic stroke neuroprotection.1 The useful clinical split is prevention in cardiometabolic patients vs. acute brain-rescue treatment after stroke onset. Research Highlights Acute neuroprotection is not established: the 2026 …
Parkinson’s disease is the second most common neurodegenerative disorder, affecting around 10 million people worldwide. The mental-health burden is heavy: depression affects 40-50% of patients9, anxiety 30-40%, sleep disorders most patients eventually, and dementia about a third of long-duration cases. Standard treatment with levodopa controls motor symptoms but doesn’t slow the underlying neurodegeneration. The clinical …
Neuroprotective agents refer to substances that are capable of preserving brain function and structure. When the brain is exposed to high levels of oxidative stress, mitochondrial dysfunction, inflammation, various forms of neurotoxicity (e.g. excitotoxicity), and protein deficiencies – neurodegeneration can occur. To prevent or mitigate the effects of any neurodegeneration, strategic administration of a neuroprotective …